Comparative pharmacokinetics of danofloxacin in healthy and Pasteurella multocida infected ducks.

摘要: Pasteurella multocida (P. multocida) infection causes substantial economic loss in the duck industry. Danofloxacin, a fluoroquinolone solely used animals, shows good antibacterial activity against P. multocida. In this study, vitro pharmacodynamics of danofloxacin P. multocida was studied. The serum and lung tissue pharmacokinetics were studied healthy infected ducks following oral administration single dose 5 mg/kg body weight (b.w.). MIC, MBC MPC (C48-1 ) 0.25, 1 3.2 μg/ml, respectively. Cmax 0.34 μg/ml, attained at 2.03 hr ducks, 0.35 μg/ml, 2.87 hr diseased ducks. Compared to absorption rate extent similar animals. contrast, elimination slower, with an half-life (T1/2β 13.17 16.18 hr for respectively; AUCs two groups 5.70 7.68 μg hr/ml, respectively, which means total amount drug circulation increased maximum concentration tissues between animals not significantly different (8.96 vs. 8.93 μg/g). However, Tmax longer than that (4 hr 1.75 hr), distribution slower approximately 24-fold higher serum. pharmacokinetic profiles, ƒAUC0-24 hr /MIC 18.19 25.04 clinical recommended dose, is far from PK/PD target (125 hr) fluoroquinolones. b.w., seems be insufficient P. multocida, MIC equal 0.25 μg/ml.